id paper:paper_00137227_v147_n9_p4438_Castillo
record_format dspace
spelling paper:paper_00137227_v147_n9_p4438_Castillo2023-06-08T14:36:13Z Retinoic acid as a novel medical therapy for Cushing's disease in dogs Giacomini, Damiana Paula Páez Pereda, Marcelo Labeur, Marta Susana alpha intermedin corticotropin creatinine hydrocortisone ketoconazole retinoic acid animal experiment animal model article controlled study corticotropin blood level creatinine urine level Cushing disease dog drug efficacy drug safety female hormone blood level hydrocortisone urine level hypophysis hypophysis adenoma male nonhuman nuclear magnetic resonance imaging priority journal survival tumor volume Adenoma Adrenocorticotropic Hormone alpha-MSH Animals Body Weight Creatinine Dog Diseases Dogs Female Hydrocortisone Ketoconazole Magnetic Resonance Imaging Male Pituitary ACTH Hypersecretion Pituitary Gland Pituitary Neoplasms Survival Rate Tretinoin Cushing's disease is almost always caused by an ACTH-secreting pituitary tumor, but effective medical therapy is currently limited. Because retinoic acid has been shown to be potentially useful in decreasing corticotroph secretion and proliferation in rodent models, we have studied its action in dogs with Cushing's disease. A randomized treatment with retinoic acid (n = 22) vs. ketoconazole (n = 20) in dogs with Cushing's disease was assigned for a period of 180 d. Clinical signs, plasma ACTH and α-MSH, the cortisol/creatinine urine ratio, and pituitary magnetic resonance imaging were assessed and compared at different time points. We recorded a significant reduction in plasma ACTH and α-MSH, and also in the cortisol/ creatinine urine ratio, of the dogs treated with retinoic acid. Pituitary adenoma size was also significantly reduced at the end of retinoic acid treatment. Survival time and all the clinical signs evaluated showed an improvement in the retinoic-acid-treated dogs. No adverse events or signs of hepatotoxicity were observed, suggesting that the drug is not only effective but also safe. Retinoic acid treatment controls ACTH and cortisol hyperactivity and tumor size in dogs with ACTH-secreting tumors, leading to resolution of the clinical phenotype. This study highlights the possibility of using retinoic acid as a novel therapy in the treatment of ACTH-secreting tumors in humans with Cushing's disease. Copyright © 2006 by The Endocrine Society. Fil:Giacomini, D. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Páez-Pereda, M. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Labeur, M. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. 2006 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00137227_v147_n9_p4438_Castillo http://hdl.handle.net/20.500.12110/paper_00137227_v147_n9_p4438_Castillo
institution Universidad de Buenos Aires
institution_str I-28
repository_str R-134
collection Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic alpha intermedin
corticotropin
creatinine
hydrocortisone
ketoconazole
retinoic acid
animal experiment
animal model
article
controlled study
corticotropin blood level
creatinine urine level
Cushing disease
dog
drug efficacy
drug safety
female
hormone blood level
hydrocortisone urine level
hypophysis
hypophysis adenoma
male
nonhuman
nuclear magnetic resonance imaging
priority journal
survival
tumor volume
Adenoma
Adrenocorticotropic Hormone
alpha-MSH
Animals
Body Weight
Creatinine
Dog Diseases
Dogs
Female
Hydrocortisone
Ketoconazole
Magnetic Resonance Imaging
Male
Pituitary ACTH Hypersecretion
Pituitary Gland
Pituitary Neoplasms
Survival Rate
Tretinoin
spellingShingle alpha intermedin
corticotropin
creatinine
hydrocortisone
ketoconazole
retinoic acid
animal experiment
animal model
article
controlled study
corticotropin blood level
creatinine urine level
Cushing disease
dog
drug efficacy
drug safety
female
hormone blood level
hydrocortisone urine level
hypophysis
hypophysis adenoma
male
nonhuman
nuclear magnetic resonance imaging
priority journal
survival
tumor volume
Adenoma
Adrenocorticotropic Hormone
alpha-MSH
Animals
Body Weight
Creatinine
Dog Diseases
Dogs
Female
Hydrocortisone
Ketoconazole
Magnetic Resonance Imaging
Male
Pituitary ACTH Hypersecretion
Pituitary Gland
Pituitary Neoplasms
Survival Rate
Tretinoin
Giacomini, Damiana Paula
Páez Pereda, Marcelo
Labeur, Marta Susana
Retinoic acid as a novel medical therapy for Cushing's disease in dogs
topic_facet alpha intermedin
corticotropin
creatinine
hydrocortisone
ketoconazole
retinoic acid
animal experiment
animal model
article
controlled study
corticotropin blood level
creatinine urine level
Cushing disease
dog
drug efficacy
drug safety
female
hormone blood level
hydrocortisone urine level
hypophysis
hypophysis adenoma
male
nonhuman
nuclear magnetic resonance imaging
priority journal
survival
tumor volume
Adenoma
Adrenocorticotropic Hormone
alpha-MSH
Animals
Body Weight
Creatinine
Dog Diseases
Dogs
Female
Hydrocortisone
Ketoconazole
Magnetic Resonance Imaging
Male
Pituitary ACTH Hypersecretion
Pituitary Gland
Pituitary Neoplasms
Survival Rate
Tretinoin
description Cushing's disease is almost always caused by an ACTH-secreting pituitary tumor, but effective medical therapy is currently limited. Because retinoic acid has been shown to be potentially useful in decreasing corticotroph secretion and proliferation in rodent models, we have studied its action in dogs with Cushing's disease. A randomized treatment with retinoic acid (n = 22) vs. ketoconazole (n = 20) in dogs with Cushing's disease was assigned for a period of 180 d. Clinical signs, plasma ACTH and α-MSH, the cortisol/creatinine urine ratio, and pituitary magnetic resonance imaging were assessed and compared at different time points. We recorded a significant reduction in plasma ACTH and α-MSH, and also in the cortisol/ creatinine urine ratio, of the dogs treated with retinoic acid. Pituitary adenoma size was also significantly reduced at the end of retinoic acid treatment. Survival time and all the clinical signs evaluated showed an improvement in the retinoic-acid-treated dogs. No adverse events or signs of hepatotoxicity were observed, suggesting that the drug is not only effective but also safe. Retinoic acid treatment controls ACTH and cortisol hyperactivity and tumor size in dogs with ACTH-secreting tumors, leading to resolution of the clinical phenotype. This study highlights the possibility of using retinoic acid as a novel therapy in the treatment of ACTH-secreting tumors in humans with Cushing's disease. Copyright © 2006 by The Endocrine Society.
author Giacomini, Damiana Paula
Páez Pereda, Marcelo
Labeur, Marta Susana
author_facet Giacomini, Damiana Paula
Páez Pereda, Marcelo
Labeur, Marta Susana
author_sort Giacomini, Damiana Paula
title Retinoic acid as a novel medical therapy for Cushing's disease in dogs
title_short Retinoic acid as a novel medical therapy for Cushing's disease in dogs
title_full Retinoic acid as a novel medical therapy for Cushing's disease in dogs
title_fullStr Retinoic acid as a novel medical therapy for Cushing's disease in dogs
title_full_unstemmed Retinoic acid as a novel medical therapy for Cushing's disease in dogs
title_sort retinoic acid as a novel medical therapy for cushing's disease in dogs
publishDate 2006
url https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00137227_v147_n9_p4438_Castillo
http://hdl.handle.net/20.500.12110/paper_00137227_v147_n9_p4438_Castillo
work_keys_str_mv AT giacominidamianapaula retinoicacidasanovelmedicaltherapyforcushingsdiseaseindogs
AT paezperedamarcelo retinoicacidasanovelmedicaltherapyforcushingsdiseaseindogs
AT labeurmartasusana retinoicacidasanovelmedicaltherapyforcushingsdiseaseindogs
_version_ 1768544067279388672